Antianginal efficacy of carvedilol, a beta-blocking drug with vasodilating activity

The American Journal of Cardiology
E A RodriguesE B Raftery


The efficacy of carvedilol, a new vasodilating beta-blocking drug, was evaluated in 20 patients with chronic angina using a single-blind, placebo-controlled protocol. A 2-week placebo phase was followed by therapy with carvedilol, 25 mg twice daily for 2 weeks, after which the dose was doubled. There was then a second placebo phase lasting 2 weeks. Treadmill exercise testing, 24-hour ambulatory electrocardiographic monitoring and drug blood level assays were performed at the end of each phase. Exercise time (mean +/- standard error of mean) increased from 7.4 +/- 0.5 minutes during placebo to 9.0 +/- 0.5 minutes carvedilol, 25 mg twice daily (p less than 0.001), and to 9.2 +/- 0.4 minutes with 50 mg twice daily (p less than 0.001). Mean time to 1 mm of ST depression in both bipolar leads CM5 and CC5 increased significantly, but peak ST depression did not change. Heart rate at rest was reduced at both dose levels, from 86 +/- 4 beats/min during placebo to 70 +/- 2 beats/min with 25 mg twice daily (p less than 0.001) and to 67 +/- 3 beats/min with 50 mg twice daily (p less than 0.001). Systolic blood pressure at rest was significantly reduced at both doses (p less than 0.05; p less than 0.01), but blood pressure during exercise w...Continue Reading


Oct 6, 1969·JAMA : the Journal of the American Medical Association·E A AmsterdamS Wolfson
Sep 1, 1966·The American Journal of Cardiology·R H GrantK Sinclair
Mar 29, 1980·Lancet·L H Opie
Nov 10, 1983·The American Journal of Cardiology·L H Opie
Mar 1, 1984·The American Journal of Cardiology·N S KhurmiE B Raftery
Sep 1, 1981·The American Journal of Cardiology·B SubramanianE B Raftery
Oct 1, 1980·British Heart Journal·V BalasubramanianE B Raftery

❮ Previous
Next ❯


Jan 1, 1992·European Journal of Clinical Pharmacology·B K KrämerT Risler
Nov 1, 1990·The American Journal of Cardiology·P Das GuptaA Lahiri
Mar 30, 2016·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Pyung Chun OhEak Kyun Shin
Jan 24, 2014·Nursing Research and Practice·Jeffrey W Young, Sheila Melander
Apr 16, 1998·Scandinavian Cardiovascular Journal. Supplement·L Hansson, A Himmelmann
Oct 16, 2012·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Carol Chen-ScarabelliTiziano M Scarabelli

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.